228 related articles for article (PubMed ID: 16564074)
21. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
22. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
[TBL] [Abstract][Full Text] [Related]
23. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.
Bristow RE; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1070-6. PubMed ID: 16875720
[TBL] [Abstract][Full Text] [Related]
24. Parenteral nutrition for patients with advanced ovarian malignancy.
Madhok BM; Yeluri S; Haigh K; Burton A; Broadhead T; Jayne DG
J Hum Nutr Diet; 2011 Apr; 24(2):187-91. PubMed ID: 21843153
[TBL] [Abstract][Full Text] [Related]
25. [Study of symptoms in terminally ill patients with ovarian carcinoma].
Sun XG; Wu M; Ma SQ; Li CY; Jin LN; Shen K
Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):192-5. PubMed ID: 17537307
[TBL] [Abstract][Full Text] [Related]
26. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
[TBL] [Abstract][Full Text] [Related]
27. Life after total laryngectomy: a measure of long-term survival, function, and quality of life.
Woodard TD; Oplatek A; Petruzzelli GJ
Arch Otolaryngol Head Neck Surg; 2007 Jun; 133(6):526-32. PubMed ID: 17576901
[TBL] [Abstract][Full Text] [Related]
28. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
[TBL] [Abstract][Full Text] [Related]
29. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
30. Short-term nutritional implications of total gastrectomy for malignancy, and the impact of parenteral nutritional support.
Ryan AM; Healy LA; Power DG; Rowley SP; Reynolds JV
Clin Nutr; 2007 Dec; 26(6):718-27. PubMed ID: 17949863
[TBL] [Abstract][Full Text] [Related]
31. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
32. Influence of the gynecologic oncologist on the survival of ovarian cancer patients.
Chan JK; Kapp DS; Shin JY; Husain A; Teng NN; Berek JS; Osann K; Leiserowitz GS; Cress RD; O'Malley C
Obstet Gynecol; 2007 Jun; 109(6):1342-50. PubMed ID: 17540806
[TBL] [Abstract][Full Text] [Related]
33. Effect of total parenteral nutrition on survival in advanced colon cancer.
Nixon DW; Lawson DH; Kutner MH; Moffitt SD; Ansley J; Heymsfield SB; Lynn MJ; Wesley M; Yancey R; Rudman D
Cancer Detect Prev; 1981; 4(1-4):421-7. PubMed ID: 6819891
[TBL] [Abstract][Full Text] [Related]
34. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment.
Aletti GD; Podratz KC; Cliby WA; Gostout BS
Gynecol Oncol; 2009 Jan; 112(1):22-7. PubMed ID: 18947860
[TBL] [Abstract][Full Text] [Related]
35. Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?
Aletti GD; Long HJ; Podratz KC; Cliby WA
Gynecol Oncol; 2007 Jan; 104(1):212-6. PubMed ID: 17023033
[TBL] [Abstract][Full Text] [Related]
36. Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer.
Eisenkop SM; Spirtos NM; Lin WC
Gynecol Oncol; 2006 Feb; 100(2):344-8. PubMed ID: 16202446
[TBL] [Abstract][Full Text] [Related]
37. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
Bae JH; Lee JM; Ryu KS; Lee YS; Park YG; Hur SY; Ahn WS; Namkoong SE
Gynecol Oncol; 2007 Jul; 106(1):193-200. PubMed ID: 17466362
[TBL] [Abstract][Full Text] [Related]
38. Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement.
Diver E; O'Connor O; Garrett L; Boruta D; Goodman A; Del Carmen M; Schorge J; Mueller P; Growdon W
Gynecol Oncol; 2013 May; 129(2):332-5. PubMed ID: 23402902
[TBL] [Abstract][Full Text] [Related]
39. Stents for palliation of obstructive metastatic colon cancer: impact on management and chemotherapy administration.
Karoui M; Charachon A; Delbaldo C; Loriau J; Laurent A; Sobhani I; Tran Van Nhieu J; Delchier JC; Fagniez PL; Piedbois P; Cherqui D
Arch Surg; 2007 Jul; 142(7):619-23; discussion 623. PubMed ID: 17638798
[TBL] [Abstract][Full Text] [Related]
40. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
